Posted by Michael Wonder on 04 Oct 2019
Recommendations made by the PBAC - August 2019 intracycle meeting
4 October 2019 - The recommendations from the August 2019 PBAC intracycle meeting are now available and have been updated.
The PBAC has recommended the listing of:
- Dolutegravir with lamivudine (Dovato)
- Ferric derisomaltose (Monofer)
- Influenza vaccine (quadrivalent, adjuvanted) - FluQuad
- Lenalidomide (Revlimid)
Dovato, Monofer and FluQuad were all deferred at the July 2019 PBAC meeting.
The PBAC decided not to recommend a broad PBS listing for the four available PD-(L)1 checkpoint inhibitors for patients with stage III/IV non-small cell lung cancer (NSCLC) at this time. However, the PBAC decided to recommend that pembrolizumab (Keytruda) be listed for first-line use in combination with chemotherapy, for patients with previously untreated stage IV, squamous EGFR/ALK/ROS1 wild-type NSCLC. The PBAC noted that this is the only group of patients with NSCLC for whom a first line PD-(L)1 PBS listing is not currently available.
